Partners in TBVAC2020 are:
Australia
University of Sydney
Belgium
Ghent University
GSK Biologicals
Scientific Institute of Public Health (WIV-ISP)
Université Libre de Bruxelles
Denmark
Statens Serum Institut (SSI)
France
Centre National de la Recherche Scientifique (CNRS)
Institut Pasteur de Lille
Institut Pasteur (Paris)
Transgene
Germany
Max-Planck-Institute for Infection Biology
Friedrich-Loeffler-Institut
University of Ulm
Ireland
Italy
Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone” di Palermo
IRCCS Lazzaro Spallanzani
Istituto Superiore Di Sanità (ISS)
Republic of Korea
Yonsei University College of Medicine
International Tuberculosis Research Center
South Africa
K-Rith Kwazulu-Natal Research Institute for Tuberculosis
South African Tuberculosis Vaccine Institute (SATVI)
Stellenbosch University
University of Cape Town
Spain
Fundació Institut d’ Investigació en Ciències de la Salut Germans Trias i Pujol
University of Zaragoza
Switzerland
Centre Hospital Universitaire Vaudois
ETH Zürich – Institute of Molecular Systems Biology
University of Basel
University of Geneva
University of Lausanne
University of Zürich
The Gambia
Medical Research Council
The Netherlands
Biomedical Primate Research Centre (BPRC)
Leiden University Medical Center (LUMC)
Tuberculosis Vaccine Initiative (TBVI)
United Kingdom
Aston University
Bangor University
Imperial College, Faculty of Medicine, Department of Medicine & School of Public Health
London School of Hygiene and Tropical Medicine (LSHTM)
The secretary of state for health (DH) acting through PHE and
MHRA
University of Oxford
Animal and Plant Health Agency (APHA)
St. George’s University of London,
United States of America
Aeras TB vaccine clinical programme was transferred in 2018 to IAVI.